Epitome Biosystems, Inc. develops and commercializes innovative protein measurement products and services to increase the productivity of drug discovery and development. The Company’s products generate valuable information about the cell signaling network, which is a key interface for monitoring drug action and understanding disease. By delivering high-value information on cell signaling networks in a condensed time frame, Epitome’s products and services are driving new research approaches for the development of drugs and diagnostics.

The Company’s products include profiling chips and assay kits, based on proprietary EpiTag™ technology, and mass spectrometry-based discovery partnerships (Q-SONAR™). EpiTag™ profiling chips and multiplex assays provide highly specific, quantitative measurements of the cell signaling network. Q-SONAR™ generates quantitative, broad-based analyses to elucidate cell network dynamics and connectivity, identify potential new targets/biomarkers and more comprehensively assess on- and off-target effects of drugs. Epitome’s technology is validated, scaleable and can be applied broadly across the drug discovery and development continuum and translated to clinical biomarker applications. Epitome partners with pharmaceutical and biotechnology companies to deliver off-the-shelf products and customized solutions.